Robert Chess, Director at NEKTAR THERAPEUTICS (NKTR), sold 10,200 shares at $0.67 ($7K) on 2022-09-22, disclosed to the SEC on 2023-09-20.
Scheduled sale ($7k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TWST | SELL | 2026-02-18 | $105K | — | Filing → |
| TWST | SELL | 2025-02-11 | $312K | — | Filing → |
| TWST | SELL | 2025-01-10 | $250K | — | Filing → |